Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells

被引:42
|
作者
Liu, Zhi-jie [1 ]
Xu, Wei [2 ]
Han, Jing [3 ]
Liu, Qing-yan [1 ]
Gao, Li-feng [1 ]
Wang, Xiao-hui [4 ]
Li, Xiu-li [1 ]
机构
[1] Chifeng Univ, Dept Pharmacol, Med Coll, Chifeng, Inner Mongolia, Peoples R China
[2] Peking Univ, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Canc Hosp & Inst,Dept Hepatopancreatobiliary Surg, Beijing, Peoples R China
[3] Capital Med Univ, Ultrasound & Funct Diag Ctr, Beijing You An Hosp, Beijing, Peoples R China
[4] Chifeng Univ, Dept Clin Lab, Affiliated Hosp, Chifeng, Inner Mongolia, Peoples R China
关键词
anticancer drugs; cancer; cyclin D1; gemcitabine; gemcitabine resistance; p53; quercetin; DRUG-RESISTANCE; CYCLE ARREST; PROLIFERATION; CYTOTOXICITY; EXPRESSION;
D O I
10.1097/CAD.0000000000000933
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Quercetin, an abundant flavonoid found in various fruits and vegetables, displays multiple biological activities, including anticancer effects. Therefore, quercetin is receiving increasing attention as a potential adjuvant anticancer treatment. Gemcitabine (GEM) resistance is a major issue for clinicians and patients with advanced cancers, making it crucial to determine ways to bolster its effects. In this study, we explored the anticancer effects and mechanistic actions of quercetin in GEM-resistant cancer cells. Pancreatic cancer (BxPC-3, PANC-1) and hepatocellular carcinoma (HepG2, Huh-7) cell lines were studied. Proliferation assays showed that quercetin had cytotoxic effects on GEM-resistant cell lines (HepG2 and PANC-1), and flow cytometric analysis indicated a significant pro-apoptotic effect on these cell lines. GEM treatment, in combination with quercetin, resulted in increased anticancer effects compared with GEM alone. Quercetin led to S phase arrest in GEM-resistant cell lines, and western blot analysis revealed tumour protein p53 upregulation and cyclin D1 downregulation. This study provides mechanistic insight into the anticancer effects of quercetin and suggests that quercetin adjuvant treatment may benefit patients who are resistant to GEM therapy.
引用
收藏
页码:684 / 692
页数:9
相关论文
共 50 条
  • [1] IFN-γ induces apoptosis in gemcitabine-resistant pancreatic cancer cells
    Kong, Xiangxin
    Cheng, Denglong
    Xu, Xu
    Zhang, Yuan
    Li, Xin
    Pan, Wanlong
    MOLECULAR MEDICINE REPORTS, 2024, 29 (05)
  • [2] Curcumin synergistically enhances the efficacy of gemcitabine against gemcitabine-resistant cholangiocarcinoma via the targeting LAT2/glutamine pathway
    Thongpon, Phonpilas
    Intuyod, Kitti
    Chomwong, Sasitorn
    Pongking, Thatsanapong
    Klungsaeng, Sirinapha
    Muisuk, Kanha
    Charoenram, Naruechar
    Sitthirach, Chutima
    Thanan, Raynoo
    Pinlaor, Porntip
    Pinlaor, Somchai
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [3] Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer
    Huang, Yen Ta
    Cheng, Chuan Chu
    Chiu, Ted H.
    Lai, Pei Chun
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (05) : 1711 - 1724
  • [4] Triptolide Cooperates With Cisplatin to Induce Apoptosis in Gemcitabine-Resistant Pancreatic Cancer
    Zhu, Wenbo
    Li, Jingjie
    Wu, Sihan
    Li, Shifeng
    Le, Liang
    Su, Xingwen
    Qiu, Pengxin
    Hu, Haiyan
    Yan, Guangmei
    PANCREAS, 2012, 41 (07) : 1029 - 1038
  • [5] Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
    Yu, Yue
    Ding, Fei
    Gao, Meng
    Jia, Yi Fu
    Ren, Le
    ONCOLOGY LETTERS, 2019, 18 (03) : 3065 - 3071
  • [6] Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine-resistant human pancreatic cancer cells
    Lin, Ji-Hua
    Chen, Sheng-Yi
    Lu, Chi-Cheng
    Lin, Jer-An
    Yen, Gow-Chin
    PHYTOTHERAPY RESEARCH, 2020, 34 (08) : 2053 - 2066
  • [7] Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
    Wu, Ying-Si
    Ho, Jar-Yi
    Yu, Cheng-Ping
    Cho, Chun-Jung
    Wu, Chia-Lun
    Huang, Cheng-Shuo
    Gao, Hong-Wei
    Yu, Dah-Shyong
    CANCERS, 2021, 13 (09)
  • [8] Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors
    Minami, Kentaro
    Shinsato, Yoshinari
    Yamamoto, Masatatsu
    Takahashi, Homare
    Zhang, Shaoxuan
    Nishizawa, Yukihiko
    Tabata, Sho
    Ikeda, Ryuji
    Kawahara, Kohich
    Tsujikawa, Kazutake
    Chijiiwa, Kazuo
    Yamada, Katsushi
    Akiyama, Shin-ichi
    Perez-Torras, Sandra
    Pastor-Anglada, Marcal
    Furukawa, Tatsuhiko
    Yasuo, Takeda
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 127 (03) : 319 - 325
  • [9] Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells
    Ahn, Hye-Mi
    Kim, Dong-Gun
    Kim, Youn-Jae
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2020, 527 (02) : 568 - 573
  • [10] Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells
    Kim, Dong Joon
    Park, Young Soo
    Kang, Min Gu
    You, Yeon-Mi
    Jung, Yuri
    Koo, Han
    Kim, Jung-Ae
    Kim, Mi-Ju
    Hong, Seung-Mo
    Lee, Kyong Bun
    Jang, Ja-June
    Park, Kyung Chan
    Yeom, Young Ii
    EXPERIMENTAL CELL RESEARCH, 2015, 336 (01) : 119 - 129